The Medical Letter on Drugs and Therapeutics
Riboflavin (Photrexa) and Ultraviolet Light for Progressive Keratoconus
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved the ophthalmic solutions riboflavin 5'-phosphate in 20% dextran (Photrexa Viscous – Avedro) and riboflavin 5'-phosphate alone (Photrexa) for use with ultraviolet A (UVA) light (KXL System) in the corneal collagen cross-linking treatment of two corneal disorders: progressive keratoconus and corneal ectasia following refractive surgery. It is the first corneal collagen cross-linking (CXL) treatment to be approved by the FDA.

THE DISORDERS — Keratoconus is a noninflammatory corneal thinning disorder with an incidence of about 1 in 1750. It usually presents in adolescence and progresses for one to two decades.1 The disorder has a variable presentation, ranging from myopic astigmatism requiring only spectacle correction to significant corneal stromal thinning, cone-like protrusion of the cornea, and corneal ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Riboflavin (Photrexa) and Ultraviolet Light for Progressive Keratoconus
Article code: 1523e
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian